Burkitt Lymphoma
72
23
28
29
Key Insights
Highlights
Success Rate
76% trial completion
Published Results
20 trials with published results (28%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
12.5%
9 terminated out of 72 trials
76.3%
-10.2% vs benchmark
4%
3 trials in Phase 3/4
69%
20 of 29 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 29 completed trials
Clinical Trials (72)
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
Allo HSCT Using RIC and PTCy for Hematological Diseases
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
Recommendations for the Treatment of Children With Burkitt's Lymphoma